The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.

In the present study, we investigated the potential activity of OSI-027, a potent and selective mammalian target of rapamycin (mTOR) complex 1/2 (mTORC1/2) dual inhibitor, against pancreatic cancer cells both in vitro and in vivo. We demonstrated that OSI-027 inhibited survival and growth of both primary and transformed (PANC-1 and MIA PaCa-2 lines) human pancreatic cancer cells. Meanwhile, OSI-027 induced caspase-dependent apoptotic death of the pancreatic cancer cells.

GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells.

Pancreatic cancer remains fatal to the fast majority of affected patients. Activation of phosphoinositide-3 kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway plays an important role in pancreatic cancer progression and chemo-resistance. In the present study, we examined the activity of GDC-0980, a novel class I PI3K/mTOR kinase inhibitor, against pancreatic cancer cells in vitro.

[Surface-enhanced raman scattering of thiabendazole adsorbed on silver nanoparticles].

In the present paper, quantum chemistry calculations method based on the density functional theory (DFT) and surface-enhanced Raman scattering (SERS) spectroscopy technique were used to investigate the adsorption behavior and enhancement effect of thiabendazole on the nanometer silver colloid surface systematically from theoretical and experimental perspective. By sodium citrate's reduction reaction, nanometer silver colloid with has high surface-enhanced Raman scattering activity was prepared. And then the authors studied the surface-enhanced Raman scattering spectroscopy of the thiabendazole in aqueous solution.